Switzerland's Auris Medical Holding AG regained compliance with Nasdaq's minimum bid price requirement of $1 per share.
However, the pharmaceuticals company is yet to regain compliance with the stock exchange's minimum $35 million market value of listed securities.
Auris has until July 10 to regain compliance with that condition.